# US 2024/0174716 A1 · Transporter peptides and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174716 A1
- Document ID: US20240174716A1
- Status: Published application
- Kind: A1
- Application number: 18/502,348
- Filed: 2023-11-06
- Published: 2024-05-30
- Earliest claimed: 2022-11-29
- Assignees: Vacino Biotech Co., Ltd.
- Applicants: Vacino Biotech Co. Ltd
- Inventors: Jia-Ming CHANG; Yi-RU LEE
- Web page: https://patentgrep.com/patent/US20240174716A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to transporter peptides that can bind to a transferrin receptor (TfR). The transporter peptides can be conjugated covalently or noncovalently to an effector agent to form a transporter peptide conjugate, or a nucleic acid encoding the transporter peptides and an effector agent is expressed to form a recombinant transporter peptide conjugate. The transporter peptide conjugate and the recombinant transporter peptide conjugate deliver the effector agent to a target by binding to a TfR. Binding of the transporter peptides to transferrin receptors on cells of a tissue barrier induces transcytosis of the cells, thereby transporting the transporter peptide conjugate across the tissue barrier. The transporter peptides can serve as a drug delivery system and used for treatment of central nervous system (CNS) diseases.

## Claims

### Claim 1

A transporter peptide, consisting of a sequence of SEQ ID NO: 1, and the transporter peptide being able to bind to a transferrin receptor (TfR).

### Claim 2 (depends on 1)

The transporter peptide of claim 1, wherein the sequence of the transporter peptide is selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 30 and variant sequences at least 70% homologous to one of SEQ ID NO: 2 to SEQ ID NO: 30 and being able to bind to the transferrin receptor.

### Claim 3 (depends on 1)

A nucleic acid encoding the transporter peptide of claim 1.

### Claim 4 (depends on 3)

The nucleic acid of claim 3, wherein the nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

### Claim 5 (depends on 1)

A vector, comprising a nucleic acid encoding the transporter peptide of claim 1.

### Claim 6 (depends on 5)

The vector of claim 5, wherein the vector is an adeno-associated virus (AAV) vector.

### Claim 7 (depends on 5)

The vector of claim 5, further comprising a nucleic acid encoding an effector agent.

### Claim 8 (depends on 7)

The vector of claim 7, wherein the effector agent is at least one selected from the group consisting of peptides, proteins, antibodies, viral particles, liposomes, endosomes, exosomes, ligands, eukaryotic cells, prokaryotic cells, and microspheres.

### Claim 9 (depends on 1)

A recombinant transporter peptide conjugate, which is expressed by a vector comprising a nucleic acid encoding the transporter peptide of claim 1 and a nucleic acid encoding an effector agent.

### Claim 10 (depends on 1)

A recombinant host cell, comprising at least one component selected from the group consisting of
the transporter peptide of claim 1;
a nucleic acid encoding the transporter peptide of claim 1; and
a vector comprising a nucleic acid encoding the transporter peptide of claim 1.

### Claim 11 (depends on 1)

A transporter peptide conjugate, consisting of the transporter peptide of claim 1 and an effector agent, and the effector agent being covalently or non-covalently conjugated to the transporter peptide.

### Claim 12 (depends on 11)

transporter peptide conjugate of claim 11, wherein the effector agent is at least one selected from the group consisting of siRNA, shRNA, microRNA, double-stranded RNA, single-stranded RNA, DNA, oligonucleotides, aptamers, genes, peptides, proteins, antibodies, small chemical molecules, large chemical molecules, viral particles, liposomes, endosomes, exosomes, nanoparticles, lipid nanoparticle, dendrimers, ligands, eukaryotic cells, prokaryotic cells, microspheres, nanogels, and bionanocapsules.

### Claim 13 (depends on 1)

A composition, comprising at least one selected from the group consisting of
the transporter peptide of claim 1;
a recombinant transporter peptide conjugate expressed by a vector comprising a nucleic acid encoding the transporter peptide of claim 1 and a nucleic acid encoding an effector agent; and
a transporter peptide conjugate consisting of the transporter peptide of claim 1 and an effector agent covalently or non-covalently conjugated to the transporter peptide.

### Claim 14 (depends on 13)

The composition of claim 13, further comprising a pharmaceutically acceptable carrier.

### Claim 15 (depends on 13)

A method of transporting the composition of claim 13 to a target, the method comprising binding the transporter peptide, the transporter peptide of the recombinant transporter peptide conjugate, or the transporter peptide of the transporter peptide conjugate to a transferrin receptor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition has to be transported across a tissue barrier to arrive at the target, and the transferrin receptor is located on a cell of the tissue barrier.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tissue barrier is one of a blood-brain barrier (BBB), a mucosal barrier, and a gastrointestinal barrier.

### Claim 18 (depends on 17)

The method of claim 17, wherein binding of the transporter peptide of the composition, the transporter peptide of the transporter peptide conjugate of the composition, or the transporter peptide of the recombinant transporter peptide conjugate of the composition to the transferrin receptor induces transcytosis of the cells, thereby transporting the composition across the tissue barrier to arrive at the target.

### Claim 19 (depends on 15)

The method of claim 15, wherein the target is a cell expressing the transferrin receptor, and the transferrin receptor is located on the target.

### Claim 20 (depends on 15)

The method of claim 15, wherein the target is in vivo or in vitro.

### Claim 21 (depends on 1)

A method of transporting an effector agent across a tissue barrier of a subject, comprising administering to the subject a recombinant transporter peptide conjugate expressed by a vector comprising a nucleic acid encoding the transporter peptide of claim 1 and a nucleic acid encoding an effector agent; or
a transporter peptide conjugate consisting of the transporter peptide of claim 1 and an effector agent covalently or non-covalently conjugated to the transporter peptide.

### Claim 22 (depends on 21)

The method of claim 21, wherein the tissue barrier is one of a blood-brain barrier (BBB), a mucosal barrier, and a gastrointestinal barrier.

### Claim 23 (depends on 22)

The method of claim 22, wherein cells of the tissue barrier express transferrin receptors.

### Claim 24 (depends on 23)

The method of claim 23, wherein the transporter peptide binds to the transferrin receptor, and the binding of the transporter peptide to the transferrin receptor induces transcytosis of the cells, thereby transporting the transporter peptide and the effector agent across the tissue barrier.

### Claim 25 (depends on 21)

The method of claim 21, wherein the recombinant transporter peptide conjugate or the transporter peptide conjugate is administered to the subject by one of intradermal delivery, intramuscular delivery, subcutaneous delivery, intravenous delivery, intra-atrial delivery, intra-articular delivery, intraperitoneal delivery, parenteral delivery, oral delivery, rectal delivery, intranasal delivery, intrapulmonary delivery, and transdermal delivery.

### Claim 26 (depends on 21)

The method of claim 21, wherein the effector agent in the recombinant transporter peptide conjugate is at least one selected from the group consisting of peptides, proteins, antibodies, viral particles, liposomes, endosomes, exosomes, ligands, eukaryotic cells, prokaryotic cells, and microspheres.

### Claim 27 (depends on 21)

The method of claim 21, wherein the effector agent consisted in the transporter peptide conjugate is at least one selected from the group consisting of siRNA, shRNA, microRNA, double-stranded RNA, single-stranded RNA, DNA, oligonucleotides, aptamers, genes, peptides, proteins, antibodies, small chemical molecules, large chemical molecules, viral particles, liposomes, endosomes, exosomes, nanoparticles, lipid nanoparticle, dendrimers, ligands, eukaryotic cells, prokaryotic cells, microspheres, nanogels, and bionanocapsules.

### Claim 28 (depends on 21)

The method of claim 21, wherein the subject is a mammal.

### Claim 29 (depends on 28)

The method of claim 28, wherein the subject is a rodent or a human.

### Claim 30 (depends on 1)

A method of treating or preventing a central nervous system (CNS) disease, comprising administering a subject in need thereof a pharmaceutically effective amount of
a recombinant transporter peptide conjugate expressed by a vector comprising a nucleic acid encoding the transporter peptide of claim 1 and a nucleic acid encoding an effector agent; or
a transporter peptide conjugate consisting of the transporter peptide of claim 1 and an effector agent covalently or non-covalently conjugated to the transporter peptide.

### Claim 31 (depends on 30)

The method of claim 30, wherein the effector agent in the recombinant transporter peptide conjugate or consisted in the transporter peptide conjugate is a therapeutic agent of the CNS disease.

### Claim 32 (depends on 30)

The method of claim 30, wherein the transporter peptide of the recombinant transporter peptide conjugate or the transporter peptide of the transporter peptide conjugate binds to a transferrin receptor on a cell of a tissue barrier of the subject, and the binding of the transporter peptide to the transferrin receptor induces transcytosis of the cell, thereby transporting the transporter peptide and the therapeutic agent of the CNS disease across the tissue barrier.

### Claim 33 (depends on 32)

The method of claim 32, wherein the tissue barrier is one of a blood-brain barrier (BBB), a mucosal barrier, and a gastrointestinal barrier.

### Claim 34 (depends on 30)

The method of claim 30, wherein the subject is a mammal.

### Claim 35 (depends on 34)

The method of claim 34, wherein the subject is a rodent or a human.

### Claim 36 (depends on 30)

The method of claim 30, wherein the recombinant transporter peptide conjugate or the transporter peptide conjugate is administered to the subject in need thereof by one of intradermal delivery, intramuscular delivery, subcutaneous delivery, intravenous delivery, intra-atrial delivery, intra-articular delivery, intraperitoneal delivery, parenteral delivery, oral delivery, rectal delivery, intranasal delivery, intrapulmonary delivery, and transdermal delivery.

### Claim 37 (depends on 30)

The method of claim 30, wherein the CNS disease is one of Alzheimer's disease (AD), Parkinson's disease (PD), cerebrovascular accidents (CVA), ascular-related dementia, Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), Traumatic Brain Injury (TBI), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's chorea, and spinal muscular atrophy (SMA).

### Claim 38 (depends on 9)

The recombinant transporter peptide conjugate of claim 9, wherein the effector agent is at least one selected from the group consisting of peptides, proteins, antibodies, viral particles, liposomes, endosomes, exosomes, ligands, eukaryotic cells, prokaryotic cells, and microspheres.

### Claim 39 (depends on 13)

The composition of claim 13, wherein the effector agent in the recombinant transporter peptide conjugate is at least one selected from the group consisting of peptides, proteins, antibodies, viral particles, liposomes, endosomes, exosomes, ligands, eukaryotic cells, prokaryotic cells, and microspheres.

### Claim 40 (depends on 13)

The composition of claim 13, wherein the effector agent consisted in the transporter peptide conjugate is at least one selected from the group consisting of siRNA, shRNA, microRNA, double-stranded RNA, single-stranded RNA, DNA, oligonucleotides, aptamers, genes, peptides, proteins, antibodies, small chemical molecules, large chemical molecules, viral particles, liposomes, endosomes, exosomes, nanoparticles, lipid nanoparticle, dendrimers, ligands, eukaryotic cells, prokaryotic cells, microspheres, nanogels, and bionanocapsules.

### Claim 41 (depends on 30)

The method of claim 30, wherein the effector agent in the recombinant transporter peptide conjugate is at least one selected from the group consisting of peptides, proteins, antibodies, viral particles, liposomes, endosomes, exosomes, ligands, eukaryotic cells, prokaryotic cells, and microspheres.

### Claim 42 (depends on 30)

The method of claim 30, wherein the effector agent consisted in the transporter peptide conjugate is at least one selected from the group consisting of siRNA, shRNA, microRNA, double-stranded RNA, single-stranded RNA, DNA, oligonucleotides, aptamers, genes, peptides, proteins, antibodies, small chemical molecules, large chemical molecules, viral particles, liposomes, endosomes, exosomes, nanoparticles, lipid nanoparticle, dendrimers, ligands, eukaryotic cells, prokaryotic cells, microspheres, nanogels, and bionanocapsules.
